As its name implies, the Actavis U.S. is the US manufacturing and marketing unit of global generics firm Actavis. The company makes some 150 generic equivalents of both prescription and OTC drugs in a number of forms, including liquids, tablets, creams, and suppositories. Actavis U.S. has manufacturing and distribution facilities in Florida, Maryland, New Jersey, and North Carolina. The group also provides contract manufacturing services to third parties. Actavis U.S. accounts for a quarter of its parents revenues. The parent has agreed to be acquired by US rival Watson Pharmaceuticals. Following the acquisition, Watson will likely integrate Actavis U.S.' products and pipeline into its existing operations.
Along with generic versions of fairly mundane drugs, (hydrocortisone creams, ibuprofen syrups), Actavis US' notable drug releases have included Kadian, an extended release morphine, the generic form of the antidepressant Wellbutrin XL, and Levetiracetam, a generic form of epilepsy drug Keppra.
Actavis US ran into some trouble at its facility in Towata, New Jersey, in 2008 after the FDA found some manufacturing violations. The plant issued a voluntary recall of about 60 medications and worked with the FDA to meet all of its requirements before restarting production in 2009. However, in 2010 Actavis consolidated its New Jersey manufacturing operations into its Elizabeth plant, which resulted in the closure of the Towata plant. The move came as part of the company's efforts to cut expenses and improve operational efficiencies.
Another voluntary recall in 2010 pulled back transdermal patches containing the strong pain management drug fentanyl. The patches were manufactured by a third-party and released the drug too quickly. No injuries were reported, but the
Actavis entered North America and created its US subsidiary in 2005 with three acquisitions: Amide Pharmaceuticals, Abrika Pharmaceuticals, and the Human Generics division of Alpharma. – less